Stockholm3 LIS Code: Stockholm3
Advanced prostate cancer risk assessment with the Stockholm3 test. Accurate private testing combining biomarkers and clinical data.
Test Categories
About this test
Overview of Stockholm3 Test
Stockholm3 is an advanced diagnostic test developed by researchers at Karolinska Institutet for the early detection of prostate cancer. It offers a significant improvement over the traditional PSA (prostate-specific antigen) test by delivering more precise and reliable results.
Superior Accuracy in Prostate Cancer Detection
Clinical studies have demonstrated that Stockholm3 identifies 100 percent more aggressive prostate cancers compared to the standard PSA test. This enhanced accuracy supports earlier and more targeted treatment interventions.
Reduction in Unnecessary Biopsies
The test has been shown to reduce unnecessary prostate biopsies by 50 percent, helping patients avoid invasive procedures when not needed, while still detecting high-risk cancers effectively.
Proven Effectiveness Through Extensive Testing
Stockholm3 has been validated in studies involving over 75,000 men. It consistently provides clear results along with specific recommendations, improving clinical decision-making and patient outcomes.
Healthcare Cost Savings
Healthcare providers in Sweden and Norway who have adopted Stockholm3 in place of the PSA test report a reduction in direct care costs ranging from 17 to 28 percent, demonstrating both clinical and economic benefits.
